Skip to main content
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Main navigation - Mobile
Beth Snyder Bulik
J&J, Bayer's Xarelto scores FDA nod in acutely ill patients
Monday, October 14, 2019
Johnson & Johnson and Bayer’s Xarelto is working to reverse a sales slide, and a new indication could help.
New Pfizer, BMS real-world data could boost Eliquis in Europe
Sunday, September 1, 2019
Pfizer and Bristol-Myers Squibb’s Eliquis has already secured a sizable lead over its rivals, and now its touting more competitor-topping data.
J&J targets different audiences with Xarelto commercial trio
Beth Snyder Bulik
Thursday, May 23, 2019
J&J and Bayer are taking Xarelto in a new direction: an ad campaign targeting specific audiences for the anticoagulant.
Xarelto scripts stagnate as discounts pile up
Tuesday, April 23, 2019
More signs of trouble for Bayer and J&J's Xarelto? As prescriptions flag, the drugmakers blame stepped-up discounts for its U.S. sales woes.
As Bayer completed the gigantic Monsanto crop science buyout in summer 2018, it started a large overhaul that will cut its animal health business, some consumer health brands and 10% of its workforce.
Bayer faces bumpy road ahead with Xarelto and Eylea
Wednesday, February 27, 2019
Bayer’s Xarelto and Eylea are still the top performers within the company’s pharma business. But both drugs are looking at a bumpy road ahead.
Chinese heparin maker banned by EMA over contamination risks
Thursday, November 29, 2018
European regulators are banning heparin from a Chinese facility after finding contamination risks with its production of the anticoagulant.
J&J's Xarelto nabs much-needed FDA nod in artery disease
Friday, October 12, 2018
The FDA approved Xarelto for chronic coronary or peripheral artery disease, an indication analysts said is worth $1.5 billion.